Published in Mol Cancer Res on January 12, 2010
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res (2013) 1.67
Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach. Curr Drug Targets (2011) 1.53
Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer (2011) 1.08
Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther (2011) 0.97
Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ (2013) 0.95
Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways. Int J Cancer (2012) 0.93
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas. Carcinogenesis (2011) 0.90
Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. World J Gastroenterol (2016) 0.83
Immunoglobulin Free Light Chains and GAGs Mediate Multiple Myeloma Extracellular Vesicles Uptake and Secondary NfκB Nuclear Translocation. Front Immunol (2014) 0.82
Cancer and diet: How are they related? Free Radic Res (2011) 0.81
Anticancer compound plumbagin and its molecular targets: a structural insight into the inhibitory mechanisms using computational approaches. PLoS One (2014) 0.80
Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget (2016) 0.75
Plant-derived anticancer agents: a promising treatment for bone metastasis. Bonekey Rep (2014) 0.75
Interventional effects of plumbagin on experimental ulcerative colitis in mice. J Nat Prod (2013) 0.75
The attenuating effects of plumbagin on pro-inflammatory cytokine expression in LPS-activated BV-2 microglial cells. J Neuroimmunol (2017) 0.75
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell (1991) 8.00
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 6.28
STATs: signal transducers and activators of transcription. Cell (1996) 6.10
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature (2001) 4.35
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci (2006) 2.44
Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol (2003) 2.44
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res (1999) 2.09
The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene (2003) 2.06
Stats: multifaceted regulators of transcription. J Interferon Cytokine Res (2005) 2.02
Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J (2002) 1.86
Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther (2006) 1.76
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood (2006) 1.73
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther (2006) 1.67
Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol (2008) 1.61
Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood (1997) 1.54
Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res (2002) 1.48
BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res (1998) 1.41
Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res (2008) 1.39
Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett (2007) 1.39
Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem (2002) 1.37
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol (2006) 1.35
Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol (1999) 1.31
Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia (2006) 1.27
Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm Res (2008) 1.24
Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci U S A (1999) 1.22
Antioxidant properties of Plumbago zeylanica, an Indian medicinal plant and its active ingredient, plumbagin. Redox Rep (2004) 1.20
Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res (2008) 1.15
Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. Eur J Cell Biol (2000) 1.10
Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse Ehrlich ascites carcinoma in vivo. Indian J Exp Biol (1998) 1.02
Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol Appl Pharmacol (2007) 1.02
Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents. Ann Oncol (2008) 1.00
Topoisomerase inhibitors as anti-arthritic agents. Inflamm Res (2008) 0.97
Radiosensitizing effects of plumbagin in cervical cancer cells is through modulation of apoptotic pathway. Mol Carcinog (2008) 0.96
Measurement and pharmacokinetic study of plumbagin in a conscious freely moving rat using liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.94
Polyunsaturated fatty acids modulate NOX 4 anion superoxide production in human fibroblasts. Biochem J (2007) 0.93
Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. Indian J Physiol Pharmacol (1997) 0.89
The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther (2007) 0.84
A naphthoquinone derivative, shikonin, has insulin-like actions by inhibiting both phosphatase and tensin homolog deleted on chromosome 10 and tyrosine phosphatases. Mol Pharmacol (2006) 0.81
[Effects of plumbagin on the human acute promyelocytic leukemia cells in vitro]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2006) 0.80
Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells. Life Sci (2003) 0.80
Temperature sensitive liposomes of plumbagin: characterization and in vivo evaluation in mice bearing melanoma B16F1. J Drug Target (2002) 0.78
Modulatory effect of plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) on macrophage functions in BALB/c mice. I. Potentiation of macrophage bactericidal activity. Immunopharmacology (1995) 0.77
Bioavailability of curcumin: problems and promises. Mol Pharm (2007) 8.72
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Inflammation and cancer: how hot is the link? Biochem Pharmacol (2006) 5.17
Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol (2007) 5.13
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) (2004) 4.01
Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett (2008) 3.61
Cancer is a preventable disease that requires major lifestyle changes. Pharm Res (2008) 3.28
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci (2008) 3.16
Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett (2008) 3.14
Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res (2009) 2.98
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol (2008) 2.95
Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J (2009) 2.89
Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol (2007) 2.70
Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol (2005) 2.62
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci (2006) 2.44
Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol (2003) 2.44
"Spicing up" of the immune system by curcumin. J Clin Immunol (2007) 2.43
Curcumin: getting back to the roots. Ann N Y Acad Sci (2005) 2.42
Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J (2012) 2.42
Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol (2002) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol (2003) 2.22
Reactive oxygen intermediates in TNF signaling. Mol Immunol (2002) 2.20
Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) (2008) 2.19
A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest (2006) 2.15
Retracted Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol (2009) 2.12
Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle (2008) 2.10
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05
Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem (2003) 2.05
Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci (2005) 2.05
Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med (2007) 2.03
NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2009) 2.03
Role of curcumin in cancer therapy. Curr Probl Cancer (2007) 2.00
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol (2005) 1.94
Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med (2012) 1.93
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92
TNF: a master switch for inflammation to cancer. Front Biosci (2008) 1.91
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Anticancer potential of silymarin: from bench to bed side. Anticancer Res (2007) 1.91
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res (2004) 1.90
Role of chemopreventive agents in cancer therapy. Cancer Lett (2004) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
The molecular inflammatory process in aging. Antioxid Redox Signal (2006) 1.86
Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery (2002) 1.83
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis (2002) 1.79
Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res (2002) 1.78
Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis (2007) 1.78
Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci (2013) 1.72
Retracted Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol (2010) 1.72
Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol (2012) 1.72
Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem (2004) 1.66
Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res (2008) 1.63
Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis (2002) 1.63
Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep (2011) 1.62
Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer (2010) 1.62
Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res (2007) 1.61
RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem (2004) 1.61
Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol (2007) 1.59
Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res (2008) 1.58
Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol (2002) 1.58
A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther (2010) 1.58
Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res (2008) 1.55
Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther (2008) 1.55
Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis (2003) 1.54
Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene (2002) 1.54
Nuclear factor-kappaB: a friend or a foe in cancer? Biochem Pharmacol (2004) 1.53